BG64680B1 - Химерен протеин на интерлевкин-6 разтворим рецептор/ лиганд, негови аналози и тяхното използване - Google Patents

Химерен протеин на интерлевкин-6 разтворим рецептор/ лиганд, негови аналози и тяхното използване Download PDF

Info

Publication number
BG64680B1
BG64680B1 BG104070A BG10407000A BG64680B1 BG 64680 B1 BG64680 B1 BG 64680B1 BG 104070 A BG104070 A BG 104070A BG 10407000 A BG10407000 A BG 10407000A BG 64680 B1 BG64680 B1 BG 64680B1
Authority
BG
Bulgaria
Prior art keywords
sil
protein
chimeric
cells
analogs
Prior art date
Application number
BG104070A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG104070A (en
Inventor
Michel Revel
Judith Chebath
Tsvee Lapidot
Orit Kollet
Original Assignee
Yeda Research And Development Co. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26323470&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG64680(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from IL12128497A external-priority patent/IL121284A0/xx
Application filed by Yeda Research And Development Co. Ltd. filed Critical Yeda Research And Development Co. Ltd.
Publication of BG104070A publication Critical patent/BG104070A/xx
Publication of BG64680B1 publication Critical patent/BG64680B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BG104070A 1997-07-10 2000-01-10 Химерен протеин на интерлевкин-6 разтворим рецептор/ лиганд, негови аналози и тяхното използване BG64680B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL12128497A IL121284A0 (en) 1997-07-10 1997-07-10 Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
IL12281897A IL122818A0 (en) 1997-07-10 1997-12-30 Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof

Publications (2)

Publication Number Publication Date
BG104070A BG104070A (en) 2000-11-30
BG64680B1 true BG64680B1 (bg) 2005-11-30

Family

ID=26323470

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104070A BG64680B1 (bg) 1997-07-10 2000-01-10 Химерен протеин на интерлевкин-6 разтворим рецептор/ лиганд, негови аналози и тяхното използване

Country Status (27)

Country Link
US (2) US7198781B1 (xx)
EP (1) EP0991661B1 (xx)
JP (1) JP4402288B2 (xx)
KR (1) KR100505172B1 (xx)
CN (1) CN1185348C (xx)
AR (1) AR013201A1 (xx)
AT (1) ATE342915T1 (xx)
AU (1) AU758161B2 (xx)
BG (1) BG64680B1 (xx)
BR (1) BR9812096B1 (xx)
CA (1) CA2295936C (xx)
CY (1) CY1105895T1 (xx)
CZ (1) CZ302488B6 (xx)
DE (1) DE69836217T2 (xx)
DK (1) DK0991661T3 (xx)
EA (1) EA004793B1 (xx)
EE (1) EE05519B1 (xx)
ES (1) ES2271999T3 (xx)
HK (1) HK1031895A1 (xx)
HU (1) HU225855B1 (xx)
IL (2) IL122818A0 (xx)
NO (1) NO327397B1 (xx)
NZ (1) NZ502139A (xx)
PL (1) PL199212B1 (xx)
PT (1) PT991661E (xx)
SK (1) SK287039B6 (xx)
WO (1) WO1999002552A2 (xx)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
US5919763A (en) * 1998-06-01 1999-07-06 Hadasit Medical Research Services And Development Company Ltd. IL-6/SIL-6R complex for promotion of liver functions
US20040170604A1 (en) 1998-07-06 2004-09-02 Tosoh Corporation IL-6 receptor IL-6 direct fusion protein
DE69941406D1 (de) * 1998-07-06 2009-10-22 Tosoh Corp IL-6 Rezeptor IL-6-gekoppeltes Fusionsprotein
WO2000053761A2 (en) * 1999-03-09 2000-09-14 Zymogenetics, Inc. Human cytokine as ligand of the zalpha receptor and uses thereof
IL130586A0 (en) 1999-06-21 2000-06-01 Yeda Res & Dev IL6RIL6 chimera for the treatment of demyelinating diseases
EP1290170A2 (en) * 2000-06-16 2003-03-12 Asterion Limited Binding agents: chimeric ligand/receptor proteins
DE60119347T2 (de) * 2000-09-14 2007-02-22 Ares Trading S.A. Verwendung von chimäres il6-il6r in huntingtonskrankheit
DE10106827A1 (de) * 2001-02-14 2002-09-05 Stefan Rose-John Verwendung eines Konjugats aus Interleukin-6(IL-6) und seinem Rezeptor zur Induktion der zellulären Expression des Stammzellfaktors (SCF) und von Flat-3-Ligand (Flt-3L)
DE10107737A1 (de) * 2001-02-16 2002-09-05 S Rose John Christian Albrecht Verwendung eines Konjugats aus IL-6 und einem IL-6 Rezeptor zur Tumortherapie
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
GB0119015D0 (en) * 2001-08-03 2001-09-26 Univ Cardiff A fusion protein
GB2389115B (en) * 2001-12-14 2005-03-16 Asterion Ltd Polypeptide having a plurality of modified growth hormone receptor binding domains of growth hormone
IL147412A0 (en) 2001-12-31 2002-08-14 Yeda Res & Dev The use of il6r/il6 chimera in nerve cell regeneration
WO2003092579A2 (en) * 2002-04-29 2003-11-13 Hadasit Medical Research Services And Development Company Ltd. Compositions and methods for treating cancer with an oncolytic viral agent
WO2004069173A2 (en) 2003-01-31 2004-08-19 The Trustees Of The University Of Pennsylvania Methods for modulating an inflammatory response
FR2850621B1 (fr) * 2003-02-04 2006-12-08 Journee Paul Connecteur reliant un bras d'essuie-glace a un balai d'essuyage, qui comporte deux languettes pour le verrouillage transversal de bras d'essuie-glace
DE10321317A1 (de) * 2003-05-13 2004-12-23 Christian-Albrechts-Universität Zu Kiel Verfahren zum Nachweis des funktionellen IL-6/ sIL-6-Rezeptor-Komplexes und Test-Kit zur Durchführung dieses Verfahrens
IL157309A0 (en) * 2003-08-07 2004-02-19 Applied Research Systems Method for the purification of a non-immunoglobulin protein
IL159558A0 (en) * 2003-12-24 2004-06-01 Applied Research Systems Use of il-6 in liver injury
IL161673A0 (en) 2004-04-29 2004-09-27 Applied Research Systems Compositions and methods for therapy of chemotherapy-induced neuropathy
IL161672A0 (en) 2004-04-29 2004-09-27 Yeda Res & Dev Compositions and methods for therapy of chemotherapy-induced neuropathy
AU2012261726B2 (en) * 2005-08-29 2015-03-12 Technion Research & Development Foundation Ltd. Media for Culturing Stem Cells
EP1962719A4 (en) 2005-08-29 2011-05-04 Technion Res And Dev Of Foundation Ltd MEDIA FOR BREEDING STEM CELLS
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
ES2612383T3 (es) 2006-07-19 2017-05-16 The Trustees Of The University Of Pennsylvania WSX-1/IL-27 como una diana para respuestas antiinflamatorias
DK3441459T3 (da) * 2006-08-02 2021-06-07 Technion Res & Dev Foundation Fremgangsmåder til ekspansion af embryonale stamceller i en suspensionskultur
WO2008100292A2 (en) 2006-10-16 2008-08-21 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods
US20090117034A1 (en) * 2007-06-15 2009-05-07 Nanhai Chen Microorganisms for imaging and/or treatment of tumors
EP2185583A2 (en) * 2007-08-03 2010-05-19 Asterion Limited Granulocyte colony stimulating factor
GB0715216D0 (en) * 2007-08-03 2007-09-12 Asterion Ltd Leptin
WO2010003118A1 (en) * 2008-07-02 2010-01-07 Trubion Pharmaceuticals, Inc. Tgf-b antagonist multi-target binding proteins
CN102264390A (zh) * 2008-07-02 2011-11-30 新兴产品开发西雅图有限公司 Il6免疫治疗
EP2387415A1 (en) 2009-01-16 2011-11-23 AGIRx Limited Vaccine compositions
EP2499236B1 (en) 2009-11-12 2020-01-01 Technion Research & Development Foundation Ltd. Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state
WO2011079308A2 (en) 2009-12-23 2011-06-30 Emergent Product Development Seattle, Llc Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
EP2614141B1 (en) 2010-09-07 2019-07-31 Technion Research & Development Foundation Limited Novel methods and culture media for culturing pluripotent stem cells
WO2013147153A1 (ja) 2012-03-29 2013-10-03 株式会社未来創薬研究所 抗ｌａｍｐ５抗体およびその利用
ES2906615T3 (es) 2013-04-19 2022-04-19 Cytune Pharma Tratamiento derivado de citocinas con síndrome de fuga vascular reducido
WO2015023505A1 (en) * 2013-08-12 2015-02-19 Merck Sharp & Dohme Corp. Methods and compositions for co-expression of polypeptides of interest and il6
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
CN104826093A (zh) * 2015-04-16 2015-08-12 刘永庆 用于治疗慢性传染性肝病的Th2免疫反应拮抗剂及卵黄抗体
CN104922659B (zh) * 2015-07-03 2018-04-20 刘永庆 防治肿瘤和/或慢性结核病的Th2免疫反应抑制剂及其应用
WO2022256688A1 (en) 2021-06-04 2022-12-08 Sonnet BioTherapeutics, Inc. Methods of treating age-related frailty with interleukin-6

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216128A (en) * 1989-06-01 1993-06-01 Yeda Research And Development Co., Ltd. IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it
IL99803A (en) * 1991-10-20 1997-02-18 Yeda Res & Dev Pharmaceutical compositions comprising interleukin-6 for the treatment of chronic lymphocytic leukemia and B-cell lymphomas
PL190445B1 (pl) * 1995-05-15 2005-12-30 Akademia Medyczna Im K Marcink Genetyczna szczepionka przeciwrakowa
DE19608813C2 (de) * 1996-03-07 1998-07-02 Angewandte Gentechnologie Syst Konjugat zur Beeinflussung von Wechselwirkungen zwischen Proteinen
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
PT1037658E (pt) * 1997-12-19 2002-10-31 Applied Research Systems Complexo ifnar2/ifn

Also Published As

Publication number Publication date
AU8127198A (en) 1999-02-08
BR9812096B1 (pt) 2011-09-06
CN1269835A (zh) 2000-10-11
CZ302488B6 (cs) 2011-06-15
JP4402288B2 (ja) 2010-01-20
BG104070A (en) 2000-11-30
ES2271999T3 (es) 2007-04-16
NO20000086L (no) 2000-03-08
CY1105895T1 (el) 2011-02-02
HUP0002426A3 (en) 2003-01-28
US20070172455A1 (en) 2007-07-26
SK287039B6 (sk) 2009-10-07
US7198781B1 (en) 2007-04-03
HK1031895A1 (en) 2001-06-29
IL122818A0 (en) 1998-08-16
WO1999002552A2 (en) 1999-01-21
AU758161B2 (en) 2003-03-20
IL133972A (en) 2015-07-30
EE200000012A (et) 2000-08-15
BR9812096A (pt) 2000-07-18
KR100505172B1 (ko) 2005-08-03
EP0991661A2 (en) 2000-04-12
CN1185348C (zh) 2005-01-19
HU225855B1 (en) 2007-11-28
EA004793B1 (ru) 2004-08-26
CA2295936A1 (en) 1999-01-21
PL338002A1 (en) 2000-09-25
CZ200075A3 (cs) 2000-08-16
EA200000109A1 (ru) 2000-08-28
ATE342915T1 (de) 2006-11-15
PT991661E (pt) 2007-01-31
DE69836217T2 (de) 2007-08-23
DK0991661T3 (da) 2007-02-05
NO327397B1 (no) 2009-06-22
KR20010021522A (ko) 2001-03-15
US7374912B2 (en) 2008-05-20
NO20000086D0 (no) 2000-01-07
AR013201A1 (es) 2000-12-13
EP0991661B1 (en) 2006-10-18
CA2295936C (en) 2009-05-26
NZ502139A (en) 2002-03-28
DE69836217D1 (de) 2006-11-30
EE05519B1 (et) 2012-02-15
PL199212B1 (pl) 2008-08-29
SK62000A3 (en) 2000-07-11
HUP0002426A2 (hu) 2000-11-28
JP2001509371A (ja) 2001-07-24
WO1999002552A3 (en) 1999-04-01

Similar Documents

Publication Publication Date Title
BG64680B1 (bg) Химерен протеин на интерлевкин-6 разтворим рецептор/ лиганд, негови аналози и тяхното използване
ES2240981T3 (es) Citocina denominada lerk-7.
ES2253753T3 (es) Citocina que induce apoptosis.
KR100320106B1 (ko) 트롬보포이에틴폴리펩티드분비방법
US8163520B2 (en) Nucleic acids encoding a chimeric polypeptide comprising IL-7 and HGF-beta chain and methods of use
ES2287773T3 (es) Composiciones y metodos relacionados con fragmentos solubles multimericos y oligomericos del receptor tweak.
AU4027799A (en) Osteoporosis treatment
EP1148065B1 (en) Fusion proteins comprising two soluble gp130 molecules
NZ238659A (en) Mast cell growth factor, recombinant production and isolated sequences
NZ501831A (en) Trail binding protein (TRAIL-BP) showing significant homology to the extracellular domains of members of the tumour necrosis factor receptor (TNF-R) and is anchored to cell surface via glycosylphosphatidylinositol (GPI) linkage
KR20000029998A (ko) 발현벡터,세포,그리고혈소판조혈인자를제조하는방법
MXPA00000364A (en) Chimeric interleukin-6 soluble receptor/ligand protein, analogs thereof and uses thereof
CA2224625A1 (en) P-selectin ligands and related molecules and methods
MXPA97004173A (en) Designated citoquina lce
MXPA97010399A (es) Citocina que induce apoptosis